Mumbai, July 23, 2025 Specialty chemical manufacturer Rossari Biotech reported a 4% year-on-year decline in its Q1 FY26 net profit, with earnings falling from ₹34.90 crore in Q1 FY25 to ₹33.60 crore in the latest quarter. Despite the dip in profit, the company showcased healthy revenue growth, highlighting resilience amid a challenging economic landscape.
💬 Leadership Speaks:
In a joint statement, Edwar Meneses, Promoter & Executive Chairman, and Sunil Chari, Promoter & Managing Director, said:
“Despite the evolving market dynamics, we’ve delivered a stable performance in Q1 FY26. Growth in our Home, Personal Care & Performance Chemicals (HPPC) and Animal Health & Nutrition (AHN) segments reflects the strength of our strategic focus. While exports saw a slight decline, our domestic business continues to remain strong, thanks to our product mix and operational initiatives.”
📈 Segment Performance & Future Outlook
The HPPC segment registered a solid 16% growth, while AHN followed closely with 12% growth.
The company is doubling down on capacity expansion, supply chain enhancements, and targeting high-growth sectors such as agrochemicals, personal care, pharmaceuticals, and oil & gas.
With new investments and commissioning underway, Rossari aims to improve operational agility and boost future profitability.
🏭 About Rossari Biotech
Headquartered in Mumbai, Rossari Biotech is a leading provider of specialty chemicals across sectors like textiles, home care, personal care, animal nutrition, and industrial performance. The company operates strategically located manufacturing units in Silvassa and Dahej, enabling efficient service to domestic and international markets.
Request a customized case study tailored to your business needs and gain deeper insights into healthcare market strategies: sales@towardshealthcare.com
The global digital health and wellness market is projected to expand from US$ 498.99 billion in 2024 to US$ 3,568.11… Read More
The global radiopharmaceutical market is projected to grow from USD 6.8 billion in 2024 to USD 14.11 billion by 2034,… Read More
The U.S. life science market is on an upward trajectory, poised to generate substantial revenue growth, potentially climbing into the… Read More
The U.S. cell therapy market size is forecast to grow at a CAGR of 21.46%, from USD 8.04 billion in… Read More
The global animal biotechnology market was USD 28.17 billion in 2024, rose to USD 30.97 billion in 2025, and is… Read More
The global ophthalmology devices market was US$ 7.51 billion in 2024, rose to US$ 7.89 billion in 2025, and is… Read More